Startseite The crystal structure of (E)-N′-(butan-2-ylidene)isonicotinohydrazide 0.5 hydrate C10H13N3O·0.5H2O
Artikel Open Access

The crystal structure of (E)-N′-(butan-2-ylidene)isonicotinohydrazide 0.5 hydrate C10H13N3O·0.5H2O

  • Itumeleng B. Setshedi ORCID logo , Andreas Lemmerer ORCID logo und Mark G. Smith ORCID logo EMAIL logo
Veröffentlicht/Copyright: 31. August 2021

Abstract

C10H13N3O·0.5H2O, orthorhombic, Aba2 (no. 41), a = 19.9676(19) Å, b = 8.4674(7) Å, c = 12.4082(10) Å, V = 2097.9(3) Å3, Z = 8, R gt (F) = 0.0299, wR ref (F 2) = 0.0849, T = 173 K.

CCDC no.: 2086756

The asymmetric unit of the title structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal: Colourless block
Size: 0.91 × 0.79 × 0.14 mm
Wavelength: Mo Kα radiation (0.71073 Å)
μ: 0.09 mm−1
Diffractometer, scan mode: Bruker D8 Venture Photon, ω
θ max, completeness: 28.0°, >99%
N(hkl) measured , N(hkl) unique, R int: 58009, 2526, 0.040
Criterion for I obs, N(hkl) gt: I obs > 2 σ(I obs), 2474
N(param) refined: 138
Programs: Bruker [1], SHELX [2], WinGX [3], PLATON [4], ORTEP-III [5]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

Atom x y z U iso*/U eq
C1 0.33289 (7) 0.36429 (17) 0.48805 (12) 0.0191 (3)
C2 0.30391 (9) 0.2671 (2) 0.41159 (14) 0.0277 (3)
H2 0.2566 0.2608 0.4052 0.033*
C3 0.34505 (11) 0.1786 (2) 0.34421 (16) 0.0359 (4)
H3 0.3247 0.1136 0.2911 0.043*
C4 0.43912 (9) 0.2735 (2) 0.42588 (16) 0.0329 (4)
H4 0.4865 0.2746 0.4321 0.039*
C5 0.40252 (8) 0.3686 (2) 0.49557 (14) 0.0247 (3)
H5 0.4243 0.4344 0.5468 0.03*
C6 0.29301 (7) 0.47594 (17) 0.55704 (12) 0.0196 (3)
C7 0.13160 (8) 0.50920 (19) 0.65346 (13) 0.0211 (3)
C8 0.09319 (8) 0.3983 (2) 0.58217 (16) 0.0295 (4)
H8A 0.118 0.3815 0.515 0.044*
H8B 0.0872 0.297 0.6192 0.044*
H8C 0.0493 0.4439 0.5657 0.044*
C9 0.09022 (8) 0.6141 (2) 0.72541 (13) 0.0235 (3)
H9A 0.0624 0.5461 0.7725 0.028*
H9B 0.0593 0.6761 0.6795 0.028*
C10 0.12885 (9) 0.7277 (2) 0.79610 (16) 0.0309 (4)
H10A 0.1608 0.7871 0.7519 0.046*
H10B 0.1532 0.6684 0.8515 0.046*
H10C 0.0976 0.8011 0.8307 0.046*
N1 0.23250 (6) 0.42502 (15) 0.58957 (12) 0.0237 (3)
H1A 0.2167 0.3325 0.5695 0.028*
N2 0.41190 (9) 0.1807 (2) 0.35055 (14) 0.0373 (4)
N3 0.19548 (7) 0.52638 (16) 0.65723 (12) 0.0238 (3)
O1 0.31550 (6) 0.60805 (13) 0.57675 (11) 0.0276 (3)
O2 0.5 0 0.20287 (16) 0.0330 (4)
H2A 0.4739 (15) 0.050 (3) 0.244 (3) 0.059 (9)*

Source of material

All reagents used were purchased and used without further purification. Isonicotinic acid hydrazide (isoniazid) (1.0 g; 7.29 mmol) and 15.0 mL of 2-butanone were added to a 25 mL stainless steel jar containing 2 × 7 mm stainless steel balls. The jar was tightly sealed and the contents were shaken for 30 min at 25 Hz using the Retsch Mixer Mill MM 200. The mixture was then transferred into a 50 ml amber Schott bottle and left slightly open to allow slow evaporation at room temperature. Colourless block crystals were observed after three days.

Experimental details

The collection method involved ω-scans of width 0.5°. Data reduction was carried out using SAINT–Plus version 6.02.6 software, and SADABS was used to process empirical absorption corrections [1]. Hydrogen atoms were allowed to ride on their respective parent atoms with d(C–H) = 0.95 [2]. Hydrogen atoms were positioned geometrically Å and U iso (H) = 1.2U eq (C). Diagrams and publication material were generated using WinGX [3], PLATON [4] and Ortep [5, 6].

Comment

Isoniazid, a synthetic derivative of nicotinic acid [7] has been used as a frontline drug for the treatment of Tuberculosis (TB) for decades [8]. Tuberculosis-causing mycobacteria have developed resistance against this drug, thus there is an urgent need for novel and effective drug design and development. Modifying existing drugs to target resistant organisms intend to mitigate the deactivation process by the mycobacteria [9]. The crystal structure being reported in this article represents a covalent modification of isoniazid. The compound crystallizes in the orthorhombic Aba2 space group. The asymmetric unit shown in the figure is a hemihydrate, containing one organic target molecule and half a water molecule. The water sits in a special position in the unit cell, with a twofold rotation axis passing through the oxygen atom of the water molecule. Bond lengths and angles are all in the expected ranges [10, 11]. The crystal packing contains bilayers of (E)-N′-(butan-2-ylidene)isonicotinohydrazide alternating with layers of water molecules. Each carbohydrazide moiety is hydrogen bonded by a O2–H2a···N2 hydrogen bond to a water molecule to form the hemihydrate. Each carbohydrazide moiety is also hydrogen bonded via its N1–H donor to the carbonyl oxygen (O1) acceptor of an adjacent carbohydrazide moiety. The water present in the crystal is generated as a byproduct of the Schiff base reaction between isoniazid and butanone and is not added to the reaction mixture.


Corresponding author: Mark G. Smith, Chemistry Department, University of South Africa, Unisa Science Campus, 28 Pioneer Avenue, Florida, Roodepoort, Gauteng, South Africa, E-mail:

Award Identifier / Grant number: 118127 and 117850

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: This work was supported by the National Research Foundation (NRF) Thuthuka Grant Number 118127 as well as Thuthuka Grant Number 117850.

  3. Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. Bruker. SAINT–Plus and SADABS; Bruker AXS Inc.: Madison, Wisconsin. USA, 2004.Suche in Google Scholar

2. Sheldrick, G. M. A short history of SHELX. Acta Crystallogr. 2008, A64, 112–122; https://doi.org/10.1107/s0108767307043930.Suche in Google Scholar PubMed

3. Farrugia, L. J. WinGX suite for small-molecule single-crystal crystallography. J. Appl. Crystallogr. 1999, 32, 837–838; https://doi.org/10.1107/s0021889899006020.Suche in Google Scholar

4. Spek, A. L. Structure validation in chemical crystallography. Acta Crystallogr. 2009, D65, 148–155; https://doi.org/10.1107/s090744490804362x.Suche in Google Scholar

5. Burnett, M. N., Johnson, C. K ORTEPIII. Report ORNL-6895; Oak Ridge National Laboratory: Tennessee, USA, 1996.Suche in Google Scholar

6. Farrugia, L. J. WinGX and ORTEP for Windows: an update. J. Appl. Crystallogr. 2012, 45, 849–854; https://doi.org/10.1107/s0021889812029111.Suche in Google Scholar

7. Pubchem. Isoniazid. Open chemistry database, 2018, 1–75. Available from https://pubchem.ncbi.nml.nih.gov/compound/isoniazid#section=Top.Suche in Google Scholar

8. Setshedi, I. B., Smith, M. G. The crystal structure of the co-crystal: 2-hydroxybenzoic acid N′-(butan-2-ylidene)pyridine-4-carbohydrazide, C10H13N3O·C7H6O3. Z. Kristallogr. N. Cryst. Struct. 2021, 236, 1093–1095; https://doi.org/10.1515/ncrs-2021-0232.Suche in Google Scholar

9. Hu, Y.-Q., Zhang, S., Zhao, F., Gao, C., Feng, L.-S., Lv, Z.-S. Isoniazid derivatives and their anti-tubercular activity. Eur. J. Med. Chem. 2017, 133, 255–267; https://doi.org/10.1016/j.ejmech.2017.04.002.Suche in Google Scholar PubMed

10. Madeley, L. G., Levendis, D. C., Lemmerer, A. Covalent- assisted supra molecular synthesis: the effect of hydrogen bonding in cocrystals of 4-tert-butyl benzoic acid with isoniazid and its derivatized forms. Acta Crystallogr. 2019, C75, 200–207; https://doi.org/10.1107/s205322961900055x.Suche in Google Scholar

11. Lemmerer, A., Bernstein, J., Kahlenberg, V. Covalent assistance in supramolecular synthesis: in situ modification and masking of the hydrogen bonding functionality of the supramolecular reagent isoniazid in co-crystals. CrystEngComm 2011, 13, 5692–5708; https://doi.org/10.1039/c1ce05152k.Suche in Google Scholar

Received: 2021-07-30
Accepted: 2021-08-16
Published Online: 2021-08-31
Published in Print: 2021-12-20

© 2021 Itumeleng B. Setshedi et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Artikel in diesem Heft

  1. Frontmatter
  2. New Crystal Structures
  3. Redetermination of the crystal structure of 3-bromonitrobenzene at 200 K, C6H4BrNO2 – temperature effects on cell constants
  4. Crystal structure of (E)-ethyl 2-((4-oxo-4H-chromen-3-yl)methyleneaminooxy)acetate, C14H13NO5
  5. Crystal structure of (8R,10R,14R, Z)-2-((3–Fluoropyridin-4-yl) methylene)-12-hydroxy-4,4,8,10,14-pentamethyl-17-((R)-2,6, 6-trimethyltetrahydro-2H-pyran-2-yl) hexadecahydro-3H-cyclopenta[a] phenanthren-3-one, C36H52FNO3
  6. Crystal structure of [6,6′-((1E,1′E)-(propane-1,3- diylbis(azaneylylidene))bis(methaneylylidene)) bis(3-chlorophenol)-κ4N,N′,O,O′] copper(II), C17H14Cl2CuN2O2
  7. The crystal structure of 6-amino-2-carboxypyridin-1-ium bromide, C6H7BrN2O2
  8. Redetermination of the crystal structure of bis[N,N′-ethylenebis(acetylacetoniminato)nickel(II)] sodium perchlorate, C24H36ClN4NaNi2O8
  9. The crystal structure of 3-methyl-2,6-dinitrophenol, C7H6N2O5
  10. The crystal structure of 5-chloro-2-(quinolin-8-yl)isoindoline-1,3-dione, C17H9ClN2O2
  11. Crystal structure of trans-tetraaqua-bis{2-carboxy-4-((5-carboxypyridin-3-yl)oxy)benzoato-κ1 N}cobalt(II) dihydrate C28H28O20N2Co
  12. Crystal structure of 3-allyl-4-(2-bromoethyl)-5-(4-methoxyphenyl)-2-(p-tolyl)furan, C23H23BrO2
  13. The crystal structure of 6,6′-(((2-(dimethylamino)ethyl)azanediyl)bis(methylene))bis(benzo[d][1,3]dioxol-5-ol ato-κ4N,N′,O,O′)-(pyridine-2,6-dicarboxylato-N,O,O′)-titanium(IV)-dichloromethane(1/1), C27H25N3O10Ti
  14. Crystal structure of (((1E,1′E)-1,2-phenylenebis(methaneylylidene))bis(hydrazin-1-yl-2-ylidene))bis(aminomethaniminium) dinitrate C10H16N10O6
  15. Crystal structure of catena-poly[triaqua-(μ 2-1,3-di(1H-imidazol-1-yl)propane-κ 2 N:N′)-(4,4′-(1H-1,2,4-triazole-3,5-diyl)dibenzoato-κ 1 O)nickel(II)]N,N′-dimethylformamide (1/1), C28H35N8O8Ni
  16. The crystal structure of 3,3′-[1,4-phenylenebis(methylene)]bis(1-ethenyl-1H-imidazol-3-ium) dichloride – dichloromethane – water (1/1/1), C19H24Cl4N4O1
  17. Crystal structure of 1,1′-(methane-1,1-diyl)bis(3-propyl-1H-imidazol-3-ium) bis(hexafluoridophosphate), C13H22F12N4P2
  18. Crystal structure of dichlorido-bis(4-chlorophenyl-κC 1)tin(IV), C12H8Cl4Sn
  19. Synthesis and crystal structure of 4-acetylpyrene, C18H12O
  20. Crystal structure of 2,2′-(butane-1,4-diylbis(azanylylidene))bis(methanylylidene))bis(4-methoxyphenol), C20H24N2O4
  21. The crystal structure of (E)-2-(((5-((triphenylstannyl)thio)-1,3,4-thiadiazol-2-yl)imino)methyl)phenol, C27H21N3OS2Sn
  22. Crystal structure of diaqua-bis(μ2-6-phenylpyridine-2-carboxylate-κ3N,O:O)-bis(6-phenylpyridine-2-carboxylato-κ2N,O)lead(II) – N,N-dimethylformamide – water (1/2/4), C54H58N6O16Pb2
  23. Crystal structure of methyl 4-acetoxy-3-methoxybenzoate, C11H12O5
  24. Crystal structure of 2,2′-(propane-1,3-dilylbis(azaneylylidene))bis(methanylylidene)bis(4-methylphenol), C19H22N2O2
  25. Crystal structure of dichlorido-bis(4-methylphenyl-κC1)tin(IV), C14H14Cl2Sn
  26. Crystal structure of methyl (E)-3-(4-acetoxyphenyl)acrylate, C12H12O4
  27. The crystal structure of bis(benzoato-κ2 O,O′)-(2,9-dimethyl-1,10-phenanthroline-κ2 N,N′)-copper(II), C28H22CuN2O4
  28. Crystal structure of (8R,10R,14R,Z)-12-hydroxy-2-((6-methoxypyridin-2-yl)methylene)-4,4,8,10,14-pentamethyl-17-((R)-2,6,6-trimethyltetrahydro-2H-pyran-2-yl)hexadecahydro-3H-cyclopenta[a]phenanthren-3-one–water (2/1), C37H56NO4.5
  29. Crystal structure of dimethyl-bis(4-bromophenyl-κC1)tin(IV), C14H14Br2Sn
  30. The crystal structure of the cocrystal di-μ2-chlorido-octamethyl-di-μ3-oxido-bis(2,3,4,5-tetrafluorobenzoato-κ2 O,O′)tetratin(IV) ─ octamethyl-di-μ3-oxido-bis(μ2-2,3,4,5-tetrafluorobenzoato-κ2 O:O′)-bis(μ2-2,3,4,5-tetrafluorobenzoato-κ2 O:O;O′)tetratin(IV) C58H54Cl2F24O16Sn8
  31. Crystal structure of 3-iodo-N 2-(2-methyl-1-(methylsulfonyl)propan-2-yl)-N 1-(2-methyl-4-(perfluoropropan-2-yl)phenyl)phthalamide, C23H22F7I1N2O4S1
  32. Crystal structure of 1-(2-(4-bromophenyl)-2,3-dihydro-1H-benzo[e]indol-1-yl)-naphthalen-2-ol – dichloromethane – dimethyl sulfoxide (1/1/1), C28H18BrNO·CH2Cl2·C2H6SO
  33. Crystal structure of [meso-5,7,7,12,14,14,-hexamethyl-1,4,8,11-tetraazacyclotetradecane]nickel(II) diperchlorate – dimethylsulphoxide (1/2), C20H48Cl2N4NiO10S2
  34. Crystal structure of 1,1′-(1,3-phenylenebis(methylene))bis(pyridin-1-ium) bis(1,2-dicyanoethene-1,2-dithiolato-κ2 S:S) palladium(II), C26H18N6PdS4
  35. The crystal structure of bis(6-phenylpyridine-2-carboxylato-κ2 N,O)copper(II), C24H16N2O4Cu
  36. Crystal structure of dichlorido-bis(4-chlorophenyl-κC)-bis(triphenylarsine oxide-κO)tin(IV), C48H38As2Cl4O2Sn
  37. Crystal structure of (4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane-κ 8 N 2, O 6) potassium cyclopentadienide, [K([2.2.2]crypt)]Cp, C23H41KN2O6
  38. The crystal structure of bis(2-oxidopyridin-1-ium-3-carboxylato-κ2O,O′)-(phenantroline-κ2N,N′)manganese(II) - methanol (1/3), C27H28N4O9Mn
  39. Crystal structure of 4-(dimethylamino)pyridinium dibromido-tris(4-chlorophenyl-κC)stannate(IV), C25H23Br2Cl3N2Sn
  40. Crystal structure of (3E,5E)-1-(4-cyanobenzenesulfonyl)-3,5-bis(3-fluorobenzylidene)piperidin-4-one-dichloromethane (1/1), C27H20Cl2F2N2O3S
  41. Crystal structure of (3E,5E)-3,5-bis(4-fluorobenzylidene)-1-((4-trifluoromethyl)benzenesulfonyl)piperidin-4-one, C26H18F5NO3S
  42. Crystal structure of chlorido-(4-methyl-2-((phenylimino)methyl)phenolato-κ2 N,O)-(pyridine-κ1 N)platinum(II), C19H17ClN2OPt
  43. Crystal structure of (4-methylbenzyl)(triphenyl)phosphonium chloride dihydrate, C26H28ClO2P
  44. The crystal structure of poly[μ2-chlorido-(μ2-1,2-bis(4-pyridyl)ethane-κ2N:N′silver(I)], C12H12AgClN2
  45. Crystal structure of poly[(μ4-benzene-1,2,4,5-tetracarboxylato)-bis(μ2-adipohydrazide)dicadmium], C11H15N4O6Cd
  46. The crystal structure of (E)-N′-(butan-2-ylidene)isonicotinohydrazide 0.5 hydrate C10H13N3O·0.5H2O
  47. The crystal structure of bis(6-phenylpyridine-2-carboxylate-κ2 N,O)-(2,2′-bipyridine-κ2 N,N′)zinc(II) monohydrate, C34H26N4O5Zn
  48. The crystal structure of (1R *,2S *)-1,2-bis(2-fluorophenyl)-3,8-dimethoxyacenaphthene-1,2-diol, C26H20F2O4
  49. Crystal structure of catena-poly[(μ2-1-((2-ethyl-4-methyl-1H-imidazol-1-yl)methyl)-1H-benzotriazole-κ2N:N′)-(nitrato-κ2O,O′)silver (I)], C13H15Ag1N6O3
  50. The crystal structure of [(phenantroline-κ2 N,N′)-bis(6-phenylpyridine-2-carboxylate-κ2 N,O)cobalt(II)]monohydrate, C36H26N4O5Co
  51. Crystal structure of (1E)-N-[(1E)-1-(4-chlorophenyl)ethylidene]-2-[1-(4-chlorophenyl)ethylidene]hydrazine-1-carbohydrazonamide, C 17 H 17 Cl 2 N 5
  52. The crystal structure of (E)-2-((tert-butylimino)methyl)-4-chlorophenol, C11H14ClNO
  53. Crystal structure of all-cis-2,4,6-trihydroxycyclohexane- 1,3,5-triaminium chloride sulfate, C6H18ClN3O7S
  54. Crystal structure of dichlorido-bis(dimethyl sulfoxide-κO)bis(4-methylphenyl-κC 1)tin(IV), C18H26Cl2O2S2Sn
  55. Crystal structure of dichlorido-bis(4-chlorophenyl-κC 1)(2,2′-bipyridyl-κ 2 N,N′)tin(IV), C22H16Cl4N2Sn
  56. Redetermination of the crystal structure of (E)-5-bromo-2-hydroxybenzaldehyde oxime, C 7 H 6 BrNO 2
  57. The crystal structure of (E)-amino(2-(4-methylbenzylidene)hydrazineyl)methaniminium 4-methylbenzoate, C9H13N4 + C8H7O2
  58. Crystal structure of 2-chloro-3-(isopentylamino)naphthalene-1,4-dione, C 15 H 16 ClNO 2
  59. The crystal structure of bis(2-acetyl-5-methoxyphenyl)carbonate 1.5 hydrate, C19H18O7
  60. The crystal structure of poly[(μ 4-4,4′-(azanediylbis(methylene))dibenzoato-κ 4 O:N:O′:Oʺ)zinc(II)], C16H13NO4Zn
  61. The crystal structure of catena-poly[(1,10-phenanthroline-k2N,N′)-(μ3-tetraoxidomoybdato(VI)-k3O:O′:O″)manganese(II)] C12H8N2O4MoMn
  62. Crystal structure of catena-poly[(4-hydroxyl-5-(methoylcarbonyl)thiophene-2-carboxylato-κ1 O)-(μ2-piperazine-1,4-diylbis(pyridin-4-ylmethanone)-κ2 N:N′)silver(I)] monohydrate, C23H23AgN4O8S
  63. Crystal structure of bis(4-bromo-2-(((3-bromopropyl)imino)methyl)phenolato-κ2N,O)-oxido-vanadium(IV), C20H20Br4N2O3V
  64. The crystal structure of (2a′S,2a1′S,3R,5a′S,7′R)-5-(furan-3-yl)-2a′,2a1′-dihydroxy-7′-methyldecahydro-2H-spiro[furan-3,6′-naphtho[1,8-bc]furan]-2,2′(2a′H)-dione, C19H22O7
  65. The crystal structure of 3-bromopicolinic acid, C6H4BrNO2
  66. Crystal structure of 1,1′-(1,4-phenylenebis(methylene))bis(pyridin-1-ium) bis(1,2-dicyanoethene-1,2-dithiolato-κ2 S,S) platinum(II), C26H18N6PtS4
  67. Synthesis and crystal structure of 5-(8-((3-carboxyazetidin-1-ium-1-yl)methyl)-7-hydroxy-4-oxo-4H-chromen-3-yl)-2-hydroxybenzenesulfonate monohydrate, C20H19NO10S
  68. The crystal structure of 3-amino-5-carboxypyridin-1-ium bromide, C6H7BrN2O2
  69. The crystal structure of (2-hydroxy-5-methyl-phenyl)-(1H-pyrazol-4-yl)-methanone hemihydrate, C11H10.5N2O2.5
  70. Crystal structure of tetraaqua-(2-(4-formylphenoxy)acetato-k1O)cadmium(II), C18H22O12Cd
  71. Crystal structure of diethyl 6,12-dimethyl-3,9-di-p-tolyl-3,9-diazapentacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5-dicarboxylate, C32H38N2O4
  72. Crystal structure of (E)-N′-(1-(3-chloro-4-fluorophenyl)ethylidene)-4-hydroxy – tetrahydrofuran (2/1), C17H16ClFN2O2.5
Heruntergeladen am 16.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2021-0311/html?lang=de
Button zum nach oben scrollen